2021.09.02
I-Mab Added to FTSE Russell Global Equity Index Series
I-Mab today announced that the Company will be added to the following FTSE Global Equity Index Series, following FTSE’s most recent semi-annual review.
2021.08.31
I-Mab Provides Business and Corporate Updates and Reports Financial Results for the Six Months Ended June 30, 2021
I-Mab today announced financial results for the six months ended June 30, 2021, and provided key business updates.
2021.08.27
I-Mab Announces Upcoming Participation at September Conferences
I-Mab today announced its participation in the following conferences in September.
2021.08.19
I-Mab Announces Establishment of Environmental, Social and Governance Committee
I-Mab today announced that its Board of Directors approved establishment of an ESG (Environmental, Social and Governance) Committee.
2021.08.17
I-Mab to Provide Business and Corporate Updates and Report Financial Results for the Six Months Ended June 30, 2021 on August 31, 2021
Conference Call Scheduled at 7:00 a.m. ET (Mandarin) and 8:00 a.m. ET (English)
2021.08.11
I-Mab Reports Positive Interim Analysis from Phase 2/3 Study of its GM-CSF Antibody Plonmarlimab (TJM2) to Treat Patients with Severe COVID-19
I-Mab today announced positive interim data from its U.S. phase 2/3 study of plonmarlimab for the treatment of cytokine release syndrome in patients with severe COVID-19.
2021.07.30
I-Mab Announces IND Approval by FDA to Initiate Phase 1 Study for Protollin for the Treatment of Alzheimer’s Disease
I-Mab today announced that the U.S. FDA has cleared the IND submission for Protollin, an investigational drug to treat Alzheimer’s disease, enabling a Phase 1 clinical trial to be initiated.
2021.07.29
I-Mab Announces Authorization of a Renewed Stock Repurchase Program by the Company up to US$40 Million
I-Mab today announced that its Board of Directors has authorized a renewed stock repurchase program.
2021.07.28
I-Mab Announces IND Acceptance for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
I-Mab today announced that an IND application for the initiation of a phase 2 clinical trial of efineptakin alfa in combination with anti-PD-1 antibody in patients with advanced solid tumors has been accepted by the CDE of the China NMPA.
2021.07.27
I-Mab Announces Preliminary Proposal for Potential Dual Listing on the STAR Market of the Shanghai Stock Exchange
The Board of Directors of I-Mab approved a preliminary proposal for the potential dual listing of the Company’s newly issued shares on the Science and Technology Innovation Board of the Shanghai Stock Exchange.